Connect with us

Technology

Lucid Group, Inc. Announces Proposed Convertible Senior Notes Offering

Published

on

NEWARK, Calif., April 2, 2025 /PRNewswire/ — Lucid Group, Inc. (Nasdaq: LCID) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2030 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Lucid also expects to grant the initial purchasers of the notes an option, for settlement within a period of 13 days from, and including, the date the notes are first issued, to purchase up to an additional $100,000,000 principal amount of notes.

The Notes

The notes will be senior, unsecured obligations of Lucid, will accrue interest payable semi-annually in arrears, and will mature on April 1, 2030, unless earlier repurchased, redeemed, or converted. Noteholders will only have the right to convert their notes in certain circumstances and during specified periods. Lucid will settle conversions of notes by paying or delivering, as applicable, cash, shares of its Class A common stock, or a combination of cash and shares of its common stock, at Lucid’s election. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Lucid’s option at any time, and from time to time, on or after April 6, 2028 and on or before the 31st scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Lucid’s common stock exceeds 130% of the conversion price for a specified period of time and certain liquidity conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.

Lucid intends to use the net proceeds of the offering, after deducting the initial purchasers’ discounts and commissions and its estimated offering expenses, to (i) repurchase a portion of its outstanding 1.25% Convertible Senior Notes due 2026 and (ii) pay the cost of the capped call transactions described below. To the extent there are any remaining net proceeds from this offering, Lucid intends to use such remainder for general corporate purposes.

Capped Call Transactions

In connection with the offering, Lucid expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers of the notes or their respective affiliates and/or other financial institutions. The capped call transactions will cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of shares of Lucid’s common stock that will initially underlie the notes. The capped call transactions are expected generally to reduce potential dilution to Lucid’s common stock upon conversion of the notes and/or offset any cash payments that Lucid could be required to make in excess of the principal amount of any converted notes upon conversion thereof, as the case may be, with such reduction and/or offset subject to a cap. If the initial purchasers exercise their option to purchase additional notes, Lucid expects to enter into additional capped call transactions with the capped call counterparties.

Repurchases of Outstanding 2026 Notes

Concurrently with the offering, Lucid expects to enter into one or more separate and individually negotiated transactions with one or more holders of the 2026 notes to repurchase for cash a portion of the 2026 notes on terms to be negotiated with each holder.

Ayar Prepaid Forward Transaction

In connection with the pricing of the notes, Lucid expects Ayar Third Investment Company (“Ayar”), a wholly-owned subsidiary of the Public Investment Fund of Saudi Arabia to enter into a privately negotiated prepaid forward transaction with a forward counterparty that is an affiliate of one of the initial purchasers, pursuant to which Ayar will purchase a number of shares of Lucid’s common stock with delivery expected to occur on or about the maturity date for the notes, subject to the ability of the forward counterparty to elect to settle all or a portion of the prepaid forward transaction early. Subject to the conditions set forth in the agreement governing the prepaid forward transaction, the prepaid forward transaction will be settled physically, subject to Ayar’s option to elect cash settlement of the prepaid forward transaction. Lucid will not be a party to the prepaid forward transaction.

The prepaid forward transaction is generally intended to facilitate privately negotiated derivative transactions, including swaps, between the forward counterparty or its affiliates and investors in the notes relating to Lucid’s common stock by which investors in the notes will hedge their investments in the notes. Ayar’s entry into the prepaid forward transaction with the forward counterparty and the entry by the forward counterparty into derivative transactions in respect of Lucid’s common stock with the investors of the notes could have the effect of increasing (or reducing the size of any decrease in) the market price of Lucid’s common stock concurrently with, or shortly after, the pricing of the notes and effectively raising the initial conversion price of the notes.

The offer and sale of the notes and any shares of Lucid’s common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of Lucid’s common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

Additional information about the transactions described in this press release can be found in the Current Report on Form 8-K that Lucid intends to file with the Securities and Exchange Commission on the same date of this press release.

About Lucid Group

Lucid (NASDAQ: LCID) is a Silicon Valley-based technology company focused on creating the most advanced EVs in the world. The award-winning Lucid Air and new Lucid Gravity deliver best-in-class performance, sophisticated design, expansive interior space and unrivaled energy efficiency. Lucid assembles both vehicles in its state-of-the-art, vertically integrated factory in Arizona. Through its industry-leading technology and innovations, Lucid is advancing the state-of-the-art of EV technology for the benefit of all.

Investor Relations Contact

investor@lucidmotors.com

Media Contact

media@lucidmotors.com

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “shall,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the anticipated terms of the notes being offered, the completion, timing and size of the proposed offering and capped call transactions, the anticipated effects of entering into the capped call transactions, the intended use of the net proceeds from the offering, including the 2026 notes repurchases, and the anticipated terms of the prepaid forward transaction. Actual events and circumstances may differ from these forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Among those risks and uncertainties are market conditions, including market interest rates, the trading price and volatility of Lucid’s common stock and risks relating to Lucid’s business, including those factors discussed under the heading “Risk Factors” in Part I, Item 1A of Lucid’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as in other documents Lucid has filed or will file with the Securities and Exchange Commission. If any of these risks materialize or Lucid’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Lucid currently does not know or that Lucid currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Lucid may not consummate the proposed offering described in this press release and, if the proposed offering is consummated, cannot provide any assurances regarding the final terms of the offering or the notes or its ability to effectively apply the net proceeds as described above. In addition, forward-looking statements reflect Lucid’s expectations, plans or forecasts of future events and views as of the date of this communication. Lucid anticipates that subsequent events and developments will cause Lucid’s assessments to change. However, while Lucid may elect to update these forward-looking statements at some point in the future, Lucid specifically disclaims any obligation to do so. Accordingly, undue reliance should not be placed upon the forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-group-inc-announces-proposed-convertible-senior-notes-offering-302418994.html

SOURCE Lucid Group

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple

Published

on

By

The article explains how sterile compounded medications are prepared to reduce the risk of contamination and support safe, customized treatments.

AZLE, Texas, July 21, 2026 /PRNewswire/ — What does sterile compounding mean for medication safety? HelloNation has published an article explaining how sterile compounding helps pharmacies prepare highly specialized medications while adhering to strict contamination-prevention procedures.

The article features insights from Laura Temple, Compounding Pharmacist Expert and Owner of Laura’s Pharmacy in Azle, Texas. It explains that sterile compounding is a specialized process for preparing medications in carefully controlled environments designed to reduce the risk of contamination. Sterile compounded medications are often used for injections, eye drops, IV medications, and other therapies that require the highest levels of cleanliness and precision.

The HelloNation article explains that sterile compounded medications differ from commercially manufactured drugs because they are prepared individually for a patient’s unique medical needs. Physicians may prescribe compounded prescriptions when a patient requires a customized dosage, a combination medication, or a treatment not commercially available. Because these medications often bypass the body’s natural defenses, medication safety depends on strict preparation standards throughout the compounding process.

The article describes how pharmacies that provide sterile compounding rely on cleanroom environments equipped with filtered-air systems, specialized equipment, and contamination-prevention protocols. Pharmacists and technicians follow detailed gowning, sterilization, and handwashing procedures before handling medication ingredients. These measures are designed to support medication safety by limiting exposure to bacteria, particles, and other contaminants.

According to the article, environmental monitoring also plays a critical role in sterile compounding. Temperature control, air quality testing, and routine equipment inspections help maintain consistent preparation standards. The article notes that sterile compounded medications may undergo additional quality assurance checks before being dispensed to patients. These procedures help support both treatment effectiveness and patient safety.

The HelloNation article also explains that pharmacies performing sterile compounding are expected to follow USP guidelines established for sterile preparation. These USP guidelines outline requirements for cleanroom pharmacy operations, environmental testing, employee training, and quality assurance practices. The article emphasizes that maintaining compliance with USP guidelines helps reinforce contamination prevention and consistent preparation standards for compounded prescriptions.

Patients seeking sterile compounded medications may also look for pharmacies that participate in accreditation programs or are overseen by state boards. The article explains that these programs review safety procedures, documentation practices, and facility standards to help maintain medication safety. Regular environmental monitoring and staff competency evaluations are also identified as important safeguards in sterile compounding operations.

The article further explains that communication between pharmacists, healthcare providers, and patients remains an important part of safe compounded prescriptions. Compounding pharmacists review prescriptions carefully, confirm dosing instructions, and evaluate ingredient compatibility before preparation begins. This collaborative approach supports medication safety by reducing the risk of errors and ensuring treatments meet individual patient needs.

The article concludes that sterile compounding continues to play an important role in healthcare, particularly for patients requiring customized therapies that are unavailable through traditional manufacturing channels. Whether preparing IV medications, injectable therapies, or other sterile compounded medications, pharmacies rely on contamination prevention procedures and strict preparation standards to support patient care. The article notes that understanding how sterile compounding works can help patients feel more informed about the safety measures involved in preparing specialized medications.

What Sterile Compounding Means for Medication Safety features insights from Laura Temple, a compounding pharmacist expert at Laura’s Pharmacy in Azle, Texas, on HelloNation.

About HelloNation

HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hellonation-article-highlights-sterile-compounding-and-medication-safety-with-insights-from-compounding-pharmacist-expert-laura-temple-302831275.html

SOURCE HelloNation

Continue Reading

Technology

CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group

Published

on

By

Regulatory demands are increasing in volume, complexity, and speed, leaving many organizations reliant on fragmented, manual approaches that slow response times and increase risk. New insights from Info-Tech Research Group show that organizations need to adopt more structured and scalable approaches to keep pace with regulatory change. The firm’s recently published blueprint, Build a Regulatory IT Response Engine, provides frameworks, tools, and step-by-step guidance to help organizations translate regulatory requirements into actionable IT controls and prioritized initiatives.

ARLINGTON, Va., July 21, 2026 /PRNewswire/ — Growing regulatory pressure across jurisdictions is forcing organizations to rethink how they interpret, prioritize, and execute compliance requirements. Many IT teams continue to operate with inconsistent processes and limited coordination, resulting in delayed initiatives and increased exposure to financial and reputational risk. Info-Tech’s blueprint, Build a Regulatory IT Response Engine, introduces a coordinated and repeatable approach to help IT leaders operationalize compliance and improve execution outcomes.

Info-Tech’s findings indicate that while organizations recognize the need for faster and more consistent regulatory response, they continue to face barriers such as fragmented interpretation of requirements, weak prioritization, and limited scalability. AI-enabled tools can help streamline analysis and accelerate response planning, but without a coordinated approach grounded in governance and human oversight, those benefits are difficult to realize.

“Regulatory response is becoming too complex to manage through disconnected, manual processes,” says Ahmad Jowhar, senior research analyst at Info-Tech Research Group. “IT leaders need a repeatable way to interpret requirements, prioritize action, and use AI to accelerate planning without losing the governance and oversight needed to execute effectively.”

Key Challenges IT Leaders Face in Regulatory Response

Despite ongoing investments in compliance, organizations continue to face systemic challenges that hinder effective execution. Info-Tech’s blueprint highlights several areas where IT and compliance leaders struggle most:

Fragmented and manual processes that slow regulatory interpretation and response.Inconsistent application of regulatory requirements across teams and jurisdictions.Poor prioritization of IT initiatives, leading to missed deadlines and duplicated effort.Limited scalability to manage increasing regulatory volume and complexity.Misalignment between compliance activities and broader business priorities.

Info-Tech’s Framework for Building a Regulatory IT Response Engine

To address these challenges, Info-Tech recommends a structured, AI-enabled approach that improves consistency, speed, and scalability. The firm’s Build a Regulatory IT Response Engine blueprint outlines the following key priorities for IT leaders:

Define the regulatory landscape: Establish organizational context, governance structures, and a centralized inventory of applicable regulations.Translate requirements into IT controls: Use AI-enabled analysis and structured assessments to convert regulatory obligations into actionable controls.Prioritize IT initiatives: Align initiatives based on cost, effort, impact, and regulatory timelines to reduce execution risk.Build and communicate a roadmap: Develop a clear, resource-aligned roadmap to guide execution and stakeholder alignment.Establish a repeatable process: Continuously monitor, adapt, and refine regulatory response capabilities to maintain compliance over time.

Organizations that adopt this structured approach can move from reactive compliance efforts to a more proactive and scalable model that shortens response timelines, reduces manual effort, and strengthens execution.

The firm’s Build a Regulatory IT Response Engine blueprint includes practical tools such as a Regulation Inventory Tool, a Regulatory Response IT Action Plan Tool, a Communication Deck Template, and a Compliance Program Framework. By applying these resources, IT leaders can standardize regulatory responses, improve prioritization, and help ensure compliance initiatives are executed on time and in alignment with business priorities.

For exclusive and timely commentary from Info-Tech’s experts, including Ahmad Jowhar, and access to the complete Build a Regulatory IT Response Engine blueprint, please contact pr@infotech.com.

About Info-Tech Research Group

Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.

To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform.

Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.

For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cios-forced-to-rethink-manual-compliance-processes-as-regulatory-complexity-rises-says-info-tech-research-group-302831286.html

SOURCE Info-Tech Research Group

Continue Reading

Technology

Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026

Published

on

By

LOS GATOS, Calif., July 21, 2026 /PRNewswire/ — Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, announced today that it plans to release its second quarter 2026 financial results after the market closes on Tuesday, Aug. 4, 2026.

The company will host a live video Zoom webinar at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Tuesday, Aug. 4, 2026, to discuss the results. The live webinar can be accessed through Atomera’s investor relations website at https://ir.atomera.com. A replay of the webcast will be available for 12 months. To pre-register for the webinar, use the following link.

https://atomera.zoom.us/webinar/register/WN_OJFbTWe1SIyV69LLdDadCw

About Atomera

Atomera Incorporated is a semiconductor materials and technology licensing company focused on deploying its proprietary, silicon-proven technology into the semiconductor industry. Atomera has developed Mears Silicon Technology™ (MST®), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-scaling technologies already in the semiconductor industry roadmap.  More information can be found at www.atomera.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/atomera-to-announce-second-quarter-2026-financial-results-and-host-webinar-on-tuesday-august-4-2026-302830602.html

SOURCE Atomera Incorporated

Continue Reading

Trending